

**CAHD
2020**

The 1st International Electronic Conference on Antioxidants in Health and Disease

01-15 DECEMBER 2020 | ONLINE

Chaired by **PROF. DR. MIHALIS I. PANAGIOTIDIS**



antioxidants



Is the antioxidant capacity of flavonoids responsible for their anticancer effects? The case of quercetin in leukemia

Gian Luigi Russo



Institute of Food Sciences – CNR - Avellino, Italy

1 – 15 December 2020



Conflict of Interest Disclosure Statement

I declare the absence of any potential or direct conflict of interest, including honoraria or other funding, related to my participation in the CAHD 2020 Virtual Conference

Acknowledgments: the lab...

Maria Grazia Volpe
Virginia Carbone
EcoNutraPrevention's group

**Institute of Food Sciences
CNR Avellino**

Maria Russo
Carmela Spagnuolo
Idolo Tedesco

Stefania Moccia

Carmen Cervellera



Paola Ungaro

IEOS
CNR Napoli

Silvestro Volpe

S.Giuseppe Moscati
Hospital Avellino

Marc Diederich
Claudia Cerella


LBMCC
(Laboratoire de
Biologie Moléculaire
et Cellulaire du
Cancer) in
Luxembourg

Anders Rosén

Linköping University
Sweden

Nicholas Carpino

Stony Brook University
L.I., New York, USA



**Institute of Food Sciences
CNR Avellino**




Overview

➤ Polyphenols in cancer: a field in *identity crisis*




➤ Molecular mechanism(s) of quercetin in Chronic Lymphocytic Leukemia: a question of *place* and *time*




Polyphenols (flavonoids) are pleiotropic compounds

Polyphenols are organic compounds present in plants where they play different biological functions. These include the regulation of enzymes involved in the metabolism and the mechanisms of defense against chemical and physical agents (UV rays, oxidative stress) or microbial (viruses, bacteria, fungi)



Chemopreventive mechanisms of polyphenols



Blocking Agents
Sulphoraphane
Flavonoid

Suppressing Agents
Curcumin
ECGG
Resveratrol
Capsaicin
 α -Bisabolol

Antioxidant activity

scavenging of free radicals and reducing oxidative stress

Phase II enzyme induction

enhancing detoxification

Phase I enzyme inhibition

blocking activation of carcinogens

Inhibition of cell proliferation

Induction of cell differentiation

Inhibition of oncogene expression

Induction of TSG

Induction of cell cycle arrest

Induction of apoptosis

Antiangiogenic activity

Inhibition of cell adhesion and invasion

Others.....

Adapted from
Liu J. Nutr. 2004, 134:3479S

The term "nutraceutical" was coined from "nutrition" and "pharmaceutical" in 1989 by Stephen DeFelice, MD, founder and chairman of the Foundation for Innovation in Medicine (FIM). According to DeFelice, nutraceutical can be defined as, "a food (or part of a food) that provides medical or health benefits, including the prevention and/or treatment of a disease..."



Recent Advances in Chemoprevention of Cancer


Waun Ki Hong^{*}, Michael B. Sporn

+ See all authors and affiliations

Chemoprevention is the use of pharmacologic or natural agents that inhibit the development of invasive cancer either by blocking the DNA damage that initiates carcinogenesis or by arresting or reversing the progression of premalignant cells (1997)




"Our endogenous antioxidant defenses are inadequate to prevent oxidative damage completely. Hence, sources of dietary antioxidants may be especially important to us" (Barry Halliwell, 1994)



The Antioxidant Hypothesis (“free radical theory”)

“Epidemiological studies have shown that high consumption of fruit and vegetables reduces risk of developing cancer and cardiovascular disease... A popular explanation refers to the presence of antioxidant nutrients, including vitamin C, vitamin E, carotenoids, selenium and flavonoids, which prevent carcinogenesis and atherogenesis by interfering *passively* with oxidative damage to DNA, lipids and proteins.... [Public Health Nutrition, 2004]



Disease prevention by fruits and vegetables



International Journal of Epidemiology, 2017, 1–28

doi: 10.1093/ije/dyw319

Original article



Original article


Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality—a systematic review and dose-response meta-analysis of prospective studies

Dagfinn Aune^{1,2,3*}, Edward Giovannucci^{4,5,6}, Paolo Boffetta⁷, Lars T. Fadnes⁸, NaNa Keum^{5,6}, Teresa Norat², Darren C. Greenwood⁹, Elio Riboli², Lars J. Vatten¹ and Serena Tonstad¹⁰




Cancer prevention by fruits and vegetables

Fruits and vegetables and total cancer, nonlinear dose-response



A

Fruits and vegetables and total cancer, per 200 g/d






ELSEVIER

Contents lists available at ScienceDirect

Seminars in Cancer Biology

journal homepage: www.elsevier.com/locate/semcancer



Review

Antioxidant polyphenols in cancer treatment: Friend, foe or foil?

Gian Luigi Russo*, Idolo Tedesco¹, Carmela Spagnuolo¹, Maria Russo¹

Institute of Food Sciences, National Research Council, 83100, Avellino, Italy



“..The controversial and contradictory issues related to the pros and cons on the use of polyphenols against cancer reflect the confounding assumption that cancer treatment and cancer prevention may overlap...”



Preclinical vs Clinical Studies

Table 1

Observational and interventional studies

published in the last 10 years where polyphenols, as single compounds or in mixtures, have been tested against different types of cancers.

Uncertain – null - negative

Table 2

Ongoing **clinical studies** retrieved (*with results*) from the ClinicalTrials.gov database on polyphenols and cancer.

No significant differences

Preclinical vs Clinical Studies

Fruit, vegetable, and fiber intake in relation to cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)¹⁻⁴

Kathryn E Bradbury, Paul N Appleby, and Timothy J Key

There was a borderline inverse association of fiber intake with breast cancer risk. For the other 9 cancer sites studied (stomach, biliary tract, pancreas, cervix, endometrium, prostate, kidney, bladder, and lymphoma) there were no reported significant associations of risk with intakes of total fruit, vegetables, or fiber. *Am J Clin Nutr* 2014;100(suppl):394S–8S.

A comprehensive meta-analysis on dietary flavonoid and lignan intake and cancer risk: level of evidence and limitations

Molecular Nutrition & Food Research, 2017

Giuseppe Grosso, Justyna Godos, Rosa Lamuela-Raventos, Sumantra Ray, Agnieszka Micek, Andrzej Pajak, Salvatore Sciacca, Nicolantonio D’Orazio, Daniele Del Rio, Fabio Galvano



Preclinical vs Clinical Studies

Table 1

Observational and interventional studies published in the last 10 years where polyphenols, as single compounds or in mixtures, have been tested against different types of cancers.

Uncertain – null - negative

Table 2

Ongoing clinical studies retrieved (*with results*) from the ClinicalTrials.gov database on polyphenols and cancer.

No significant differences



Preclinical vs Clinical Studies

open
Biology

Oxidants, antioxidants and the current incurability of metastatic cancers


Jim Watson

Open Biol. 2013 **3**, 120144, published online 8 January 2013

“free radical-destroying antioxidative nutritional supplements may have caused more cancers than they have prevented....”





Antioxidants vs cancer cells



Sayin et al. ScienceTranslational Medicine, 2014

Quercetin



Food	Quercetin	
Lettuce	0.7-0.3	mg/100g
Onion	28.4-48.6	mg/100g
Apple	2.1-7.2	mg/100g
Strawberry	0.8-1.0	mg/100g
Black tea	1.7-2.5	mg/100ml
Red wine	0.4-1.6	mg/100ml
Apple juice	0.3	mg/100ml


Polyphenols	1-2 g/day	
Flavonoids	1 g/day	
Flavonol glycoside	100 mg/day	
Quercetin	5-40 mg/day	200-500 mg/day (7 mg / Kg)




Quercetin: not apoptotic but pro-apoptotic

Traditional cancer therapy can activate apoptosis, but can encounter **tumour resistance**. Promising results to bypass resistance are expected from protocols of “*combination therapy*” approach, where canonical drugs and/or naturally occurring chemotherapeutic agents can be associated with natural occurring agents.

Molecule	↓ROS(%)	↑Apoptosis (%)
Quercetin 50 μ M	60	>50
(+) Catechin 100 μ M	40	0
Myricetin 50 μ M	50	10
Quercetrin 50 μ M	40	0
Resveratrol 30 μ M	0	10
Gallic Acid 12 μ M	0	10



Quercetin








Catechin



Myricetin


Quercetin enhances apoptosis in cell lines





Chronic Lymphocytic Leukemia (CLL)

- ❖ CLL is one of the most common leukemia in adult population (22-30% of all leukemia cases). In 2016, 18,960 new cases in USA with 4660 deaths.
- ❖ CLL is defined a malignant lymphoproliferative disorder of mature clonal B lymphocytes that accumulate in the blood and other lymphoid tissues.
- ❖ The diagnosis of CLL occurs when B-cells count is $>5,000/\mu\text{L}$
- ❖ Poor diagnosis and shorter time to treatment and survival is more pronounced for CLL expressing Zap-70 and those with high level of CD38 (both markers are highly expressed in IGHV-UM CLL)
- ❖ CLL is an highly heterogeneous and still an incurable disease. Most treated patients became resistant to common chemotherapeutic drugs (combination immunochemotherapy: fludarabine, cyclophosphamide and rituximab, anti-CD20 MAb).
- ❖ B-cells are resistant to DR-induced apoptosis


Can Quercetin induce Apoptosis in B-CLL?



BH-3 “mimetic” ABT-737



BH3-only Pro-apoptotic proteins



Anti-apoptotic proteins





Multidomain pro-apoptotic proteins




APOPTOSIS

Adapted from S.-L. Khan et al., Pathology, 2011

Quercetin and ABT-737 in B-CLL




Quercetin and ABT-737 in PBMC



Russo M, Spagnuolo Biochem. Pharmacol., 2013



Quercetin and ABT-737 can bypass resistance in B-cells



HG3-CLL Cell Line (the “ideal” cellular model)



Anders Rosén
(Linköping University, Sweden)

Oncolmmunology 1:1, 18–27; January/February 2012; © 2012 Landes Bioscience


Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by *in vitro* EBV infection

Anders Rosén,^{1*} Ann-Charlotte Bergh,¹ Peter Gogolák,^{2†} Chamilly Evaldsson,¹ Anna Lanemo Myhrinder,¹ Eva Hellqvist,¹ Abu Rasul,² Magnus Björkholm,³ Mattias Jansson,⁴ Larry Mansouri,⁴ Anquan Liu,^{2‡} Bin Tean Teh,⁵ Richard Rosenquist⁴ and Eva Klein^{2*}

- HG3 established by *in vitro* EBV-infection;
- Derives from an IGHV1–2 unmutated CLL patient clone;
- Biallelic 13q14 deletions with genomic loss of DLEU7, miR15a/miR16–1, the two micro-RNAs that are deleted in 50% of CLL cases;
- Expression of CD5/CD20/CD27/CD43
- G-banding are showing identical biallelic deletions of chromosome 13 in HG3 cell line and in HG patient





Quercetin Enhances Apoptosis in HG3-CLL



Russo M. et al. Unpublished



Quercetin Down-regulates PI_3K -Akt Pathway in HG3-CLL



Quercetin as a direct inhibitor of PI₃K

Table 2 Cellular kinases directly targeted by quercetin

Targets	Binding site	Concentration	Cellular effects	Reference
MEK-1	Activation loop	1–2 μM	Apoptosis Cell cycle Growth arrest	[49, 56, 58]
PI ₃ Kγ	ATP-binding site	3.8 μM	Apoptosis Cell cycle Growth arrest	[105]
IKK α/β	ATP- and IκBα-binding sites	IC ₅₀ 11 μM (α)	Apoptosis	[77]



Molecular Cell, Vol. 6, 909–919, October, 2000, Copyright ©2000 by Cell Press

Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine

Edward H. Walker,* Michael E. Pacold,* Olga Perisic,*




Quercetin inhibits PI_3K activity in HG3-CLL



Russo M. et al., Oncotarget, 2017


DPBA Staining of Quercetin in HG3-CLL




Russo M. et al., Oncotarget, 2017




Time-dependent down-regulation of Akt/Mcl-1 (the time..)




Russo M. et al., Oncotarget, 2017



CK2 (Casein Kinase 2) in CLL





Adapted from Piazza et al., Leukemia, 2012




Adapted from Prins et al., Leukemia, 2013

Quercetin Inhibits CK2 activity in HG3-CLL



Russo M. et al., *Oncotarget* 2017

Quercetin mechanism of action



Russo M. et al., Oncotarget, 2017



Conclusions

- Quercetin sensitizes synergistically human malignant cell lines **AND** B-cells isolated from CLL patients to conventional (fludarabine) and novel (BH3-mimetics, ABT-737) treatments;
- In CLL-derived cells, quercetin targets primarily protein kinases (CK2 and PI₃K) which positively regulate the **PI₃K-AKT-Mcl1** pathway;
- Quercetin cytotoxicity on normal peripheral blood leukocytes is acceptable;

CONSIDERING THAT

- Phase I clinical trial in humans established a recommended dose of 1400 mg/m² (2.5 g/70 Kg) intravenous weekly interval.
- **Overall, these data indicate the potential therapeutic use of quercetin against CLL**

Acknowledgments

*Regional Products
with Healthy
Properties to
Develop New
Functional Foods
(**RiSaNA**)*



*Well-being from Biotechnology:
Innovative Processes and Products
to Ameliorate Nutraceuticals,
Cosmeceuticals and Human Nutrition
(**BenTeN**)*



PO FESR 2014-2020 –CAMPANIA TERRA DEL BUONO”
RIS3 Oncologia
Progetto *EcoNutraPrevention*